Article
Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing.
Molecular diagnosis & therapy - 1 Dec 2019
Ritterhouse Lauren L, Parilla Megan, Zhen Chao Jie, Wurst Michelle N, Puranik Rutika, Henderson Candace M, Joudeh Neda Z, Hartley Madeline J, Haridas Rishikesh, Wanjari Pankhuri, Furtado Larissa V, Kadri Sabah, Segal Jeremy P
Abstract excerpt
BACKGROUND: Nucleophosmin 1 (NPM1) is one of the most commonly mutated genes in acute myeloid leukemia, with mutations observed in approximately 30% of all adult cases. The persistence of NPM1 mutations following chemotherapy is associated with a greater risk of relapse as well as a lower rate of survival, making NPM1 measurable residual disease (MRD) an informative clinical target. METHODS: Herein, we have...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.